Compare FXNC & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FXNC | ELDN |
|---|---|---|
| Founded | 1907 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.5M | 300.3M |
| IPO Year | 2012 | 2014 |
| Metric | FXNC | ELDN |
|---|---|---|
| Price | $28.27 | $3.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 62.4K | ★ 1.1M |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | ★ 96.00 | 30.67 |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $7,717,000.00 | N/A |
| Revenue This Year | $12.21 | N/A |
| Revenue Next Year | $2.93 | N/A |
| P/E Ratio | $51.70 | ★ N/A |
| Revenue Growth | ★ 7.40 | N/A |
| 52 Week Low | $18.35 | $1.35 |
| 52 Week High | $29.85 | $4.60 |
| Indicator | FXNC | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 58.70 | 58.68 |
| Support Level | $26.39 | $3.35 |
| Resistance Level | $28.66 | $4.14 |
| Average True Range (ATR) | 0.79 | 0.21 |
| MACD | 0.12 | -0.02 |
| Stochastic Oscillator | 82.48 | 65.07 |
First National Corp is a bank holding company of First Bank, which is a commercial bank. Its core offering includes loans, deposits, wealth management, and other products and services. The Company operates through two reportable operating segments: Community Banking and wealth management. The Community Banking segment involves making loans and generating deposits from individuals, businesses, and charitable organizations. Wealth Management Services offers corporate trustee services, trust and estate administration, IRA administration and custody services. The company has revenue from Community Banking segment.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.